Fluid Management and Individualized Resuscitation in Sepsis
NCT07009665 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 188
Last updated 2025-12-19
Summary
The goal of this clinical trial is to find out if a personalized treatment approach can improve care for people with sepsis in the emergency department (ED).
Sepsis is a life-threatening condition that happens when the body has an uncontrolled response to an infection. This can lead to low blood pressure, organ failure, and death if not treated quickly. Right now, most people with sepsis receive a standard amount of fluids to raise their blood pressure. But this one-size-fits-all approach can lead to fluid overload and other complications. Because each person responds differently, this study will test whether a more personalized treatment-based on how the heart responds to fluids-can lead to safer and more effective care.
The study will include 188 adults who come to the ED at the University Medical Centre Groningen (UMCG) with suspected sepsis in need of hemodynamic resuscitation. Everyone in the study will receive fluids to support their blood pressure.
Participants will be randomly assigned to one of two groups:
* Personalized treatment group: Fluids and vasopressors (medications that raise blood pressure) will be given based on how the heart responds to each fluid dose. This response is measured using a non-invasive monitor that tracks stroke volume index (ΔSVI)-a measure of how much blood the heart pumps.
* Standard care group: Fluids will be given based on current guidelines (30 milliliters per kilogram of body weight), as decided by the treating doctor.
Researchers will compare how much fluid is given during the first 3 hours of care. They will also look at:
* When and how much vasopressor medicine is used
* How well blood pressure and circulation respond
* Signs of organ recovery or damage
* How long participants stay in the hospital
* Any problems or side effects during treatment
The researchers hope that this personalized approach will lead to using less fluid, starting vasopressors earlier, and helping people with sepsis recover more safely and quickly.
Conditions
- Sepsis
- Shock
- Personalized Medicine
- Emergency Medicine
- Critical Care, Fluid Resuscitation
- Fluid Responsiveness
Interventions
- OTHER
-
Personalized SV-guided resuscitation
Participants will receive an IV fluid bolus directly after inclusion. Next, measurement of the cardiac output change in response to the fluid bolus by the Starling SV will be used to determine fluid responsiveness. Vital parameters and fluid responsiveness will be used to guide hemodynamic resuscitation, consisting of IV fluids and/or vasopressors, during the first 3 hours.
- OTHER
-
Standard Care Resuscitation
In the control group, IV fluid and vasopressor administration will be determined at the discretion of the physician and in accordance with currently available guidelines (e.g. Sepsis Surviving Campaign).
Sponsors & Collaborators
-
University Medical Center Groningen
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-01
- Primary Completion
- 2026-09-01
- Completion
- 2026-12-01
Countries
- Netherlands
Study Locations
More Related Trials
-
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2
NCT06062303 ·Status: RECRUITING ·Phase: NA
-
Cardiac Output Monitoring Managing Intravenous Therapy (COMMIT) to Treat Emergency Department Severe Sepsis
NCT01484106 ·Status: COMPLETED ·Phase: NA
-
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
NCT03434028 ·Status: COMPLETED ·Phase: PHASE3
-
The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial
NCT03668236 ·Status: COMPLETED ·Phase: PHASE4
-
Personalized Swiss Sepsis Study
NCT04130789 ·Status: RECRUITING
-
Fluid Intolerance Signals as Safety Limits to Prevent Fluid-induced Harm During Septic Shock Resuscitation
NCT06568744 ·Status: RECRUITING ·Phase: NA
-
HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients
NCT03710187 ·Status: COMPLETED ·Phase: PHASE2
-
Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis
NCT00484133 ·Status: UNKNOWN ·Phase: PHASE4
-
Early Vasopressors in Sepsis
NCT05179499 ·Status: RECRUITING ·Phase: PHASE3
-
Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis
NCT02885688 ·Status: WITHDRAWN ·Phase: PHASE2
-
Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock
NCT06746753 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis
NCT04280497 ·Status: RECRUITING ·Phase: NA
-
Sepsis: From Syndrome to Personalized Care
NCT04203979 ·Status: RECRUITING
-
Protocolized Reduction of Non-resuscitation Fluids vs Usual Care in Septic Shock Feasibility Trial
NCT05249088 ·Status: COMPLETED ·Phase: NA
-
Protocolized Reduction of Non-resuscitation Fluids Versus Usual Care in Septic Shock Patients
NCT06140147 ·Status: RECRUITING ·Phase: NA
-
Hemodynamic Phenotype and Capillary Refill Time-targeted Resuscitation Strategy
NCT05057611 ·Status: RECRUITING ·Phase: NA
-
Fluid Resuscitation in Early Septic Shock
NCT00819416 ·Status: COMPLETED ·Phase: PHASE2
-
Shock and Acute Conditions OutcOmes Platform
NCT06376318 ·Status: ACTIVE_NOT_RECRUITING
-
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
NCT00279214 ·Status: COMPLETED ·Phase: PHASE4
-
Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock
NCT02972827 ·Status: UNKNOWN ·Phase: NA
-
Hyperoxia and Hypertonic Saline in Septic Shock
NCT01722422 ·Status: TERMINATED ·Phase: NA
-
External Cooling in Septic Shock Patients
NCT00527007 ·Status: COMPLETED ·Phase: NA
-
Protocolised Early De-Resuscitation in Septic Shock (REDUCE)
NCT04931485 ·Status: COMPLETED ·Phase: NA
-
Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
NCT02266589 ·Status: COMPLETED ·Phase: PHASE3
-
Molecular Diagnosis and Risk Stratification of Sepsis
NCT01905033 ·Status: UNKNOWN